New drug cocktail aims to rescue HIV patients when other treatments fail

NCT ID NCT00196625

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three HIV drugs (amprenavir, lopinavir, and ritonavir) in patients whose current treatments are no longer working. The goal is to see if this new mix can lower the amount of HIV in the blood over 26 weeks. Participants are HIV-positive adults who have tried multiple previous therapies without success. The study compares two different doses of ritonavir to find the safest and most effective option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: amprenavir, lopinavir, and ritonavir
What this could lead to: If successful, this combination could offer a new treatment option for people with HIV who have not responded to other therapies.
What could go wrong: This is a Phase 2 trial with only 100 participants, so results may not apply to everyone. The drugs can cause side effects and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.